Intravacc, Versatope to develop universal flu vaccine

By The Science Advisory Board staff writers

June 8, 2020 -- Dutch vaccine developer Intravacc and biotechnology firm Versatope have signed an agreement to collaborate on a universal influenza vaccine.

Intravacc will support Lowell, MA-based Versatope in bringing its universal influenza vaccine candidate VT-105 to clinical trial; the vaccine will include Intravacc's outer membrane vesicles (OMV) technology, the two companies said.

The companies hope that the OMV technology will provide better cross-strain protection than other influenza vaccines that consist of individual strains.


Copyright © 2020 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.